HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Clinical trials for HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER trials appear
Sign up with your email to follow new studies for HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental ovarian cancer drug combo studied in early trial
Disease control TerminatedThis early-phase trial tested a new drug called STRO-002 combined with Avastin (bevacizumab) in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the right dose. The study was terminated early, so while it …
Matched conditions: HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC